FT : Aston Martin to raise more than £500mn through Saudi fund and rights issue

Aston Martin to raise more than £500mn through Saudi fund and rights issue
Luxury carmaker’s board to vote on proposal to bring in one of the world’s largest investors as a shareholder

Aston Martin is closing in on a deal to raise significantly more than £500mn by bringing in Saudi Arabia’s sovereign wealth fund as a major shareholder and holding a rights issue for investors, according to two people.

The luxury carmaker’s board will meet on Thursday evening to discuss the fundraising plan, which is expected to be announced as early as Friday, the people said.

The proposal will result in the kingdom’s Public Investment Fund, PIF, investing up to £200mn for a shareholding of slightly less than 20 per cent and a seat on the carmaker’s board.

PIF is one of the world’s largest investors, and owns stakes in electric carmaker Lucid and British supercar group McLaren.

The planned financing would also involve Aston launching a rights issue for investors that will be at least £300mn, and could be considerably higher.

The exact size of the rights issue will be decided in the board meeting, the people added. Chair Lawrence Stroll and his Yew Tree investment consortium have already agreed to take up their options.

Aston’s board has also recently received a separate investment proposal from China’s Geely, which it will consider during Thursday’s meeting, three people said.

The Chinese carmaker’s proposal includes both an equity investment and a wider collaboration with the global Geely family of brands, which includes Lotus and Volvo Cars, one of the people said. Geely is also a shareholder in Mercedes-Benz, which itself holds a stake in Aston.

Aston Martin and Geely declined to comment. A representative for PIF did not respond to a request for comment.

The money will be used to pay down the company’s debt, helping it become cash positive and driving away persistent investor fears about the business’s financial health.

The group had £957mn of net debt at the end of March, and last quarter said it expects to pay about £130mn in debt interest this year.

Aston Martin has been seeking additional funding for its next generation of sports cars and as it prepares to branch into electric models.

The fundraising is the latest move by owner and chair Stroll to try to shore up the business during a turnround that aims to restore its luxury credentials and make the brand highly profitable by the middle of the decade.

Stroll has an existing relationship with Saudi Arabia’s Aramco, which joined Aston Martin’s Formula One team as a named partner earlier this year. Raising the brand’s profile through racing is part of Stroll’s strategy to attract buyers, along with launching mid-engine supercars to take on Ferrari.

The company wants to release its first all-electric sports car in 2025, yet will need to invest in the programme. It is also expected to unveil a refreshed line-up of its sports car range.

>>> US Research Calls

Research Calls

  • Upgrades:
    • Centene (CNC) upgraded to Buy from Hold at Jefferies; tgt raised to $115
    • Costco (COST) upgraded to Buy from Hold at Deutsche Bank; tgt raised to $579
    • Empire State Realty Trust (ESRT) upgraded to Market Perform from Underperform at BMO Capital Markets; tgt raised to $8
    • Flywire (FLYW) upgraded to Buy from Neutral at Goldman; tgt raised to $30
    • IDEX Corp (IEX) upgraded to Outperform from Perform at Oppenheimer; tgt $215
  • Downgrades:
    • A.O. Smith (AOS) downgraded to Neutral from Outperform at Robert W. Baird; tgt $60
    • American Assets Trust (AAT) downgraded to Sector Weight from Overweight at KeyBanc Capital Markets
    • Cardlytics (CDLX) downgraded to Equal Weight from Overweight at Wells Fargo; tgt lowered to $15
    • Cigna (CI) downgraded to Hold from Buy at Jefferies; tgt lowered to $271
    • ContraFect (CFRX) downgraded to Mkt Perform from Outperform at SVB Leerink; tgt $1
    • ContraFect (CFRX) downgraded to Neutral from Overweight at Cantor Fitzgerald; tgt lowered to $1
    • Dollar General (DG) downgraded to Neutral from Buy at Citigroup; tgt $258
    • Edison (EIX) downgraded to Underperform from Neutral at BofA Securities
    • Fastenal (FAST) downgraded to Neutral from Outperform at Robert W. Baird; tgt $48
    • Fidelity Nat'l Info (FIS) downgraded to Equal Weight from Overweight at Wells Fargo; tgt lowered to $101
    • Fiserv (FISV) downgraded to Equal Weight from Overweight at Wells Fargo; tgt lowered to $97
    • Franklin Electric (FELE) downgraded to Neutral from Outperform at Robert W. Baird; tgt $75
    • Graco (GGG) downgraded to Neutral from Outperform at Robert W. Baird; tgt $61
    • Hayward Holdings (HAYW) downgraded to Neutral from Outperform at Robert W. Baird; tgt $16
    • JELD-WEN (JELD) downgraded to Equal Weight from Overweight at Barclays; tgt lowered to $17
  • Others:
    • Albemarle (ALB) named Catalyst Call: Buy Idea at Deutsche Bank
    • Avnet (AVT) initiated with an Underweight at JP Morgan; tgt $46
    • CF Industries (CF) initiated with an Underperform at Credit Suisse; tgt $73
    • Corteva (CTVA) initiated with an Outperform at Credit Suisse; tgt $68

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:

  • ERIC -9.7%, AZTA -6.3% (lowers guidance for JunQ revs), JPM -2.9%, WELL -1.1%, CAG -1.1%, MS -0.9%

Select metals/mining stocks trading lower:

  • AU -3.8%, GFI -3.7%, GDX -2.2%, GOLD -2.2%, BTG -2.1%, IAG -2.1%, SLV -2%, GLD -1.1%

Select oil/gas related names showing early weakness:

  • TTE -4.3%, SHEL -3.3%, BP -3%, OIH -2.4%, HAL -2.2%, COP -2.1%, XLE -2%, SLB -1.8%, PSX -1.8%, USO -1.7%

Other news:

  • CFRX -77.2% (independent DSMB recommends Exebacase Phase 3 DISRUPT Study be stopped)
  • BLU -8.8% (prices offering of 16540541 common shares at $9.25 per common share)
  • EGY -8.8% (Transglobe Energy to be acquired by VALLCO Energy (EGY) in stock-for-stock strategic business combination)
  • COKE -5.1% (to move to S&P MidCap 400 from SmallCap 600)
  • NVAX -3% (FDA authorizes NVAX's COVID-19 vaccine for adults)
  • TSLA -1.6% (Tesla Autopilot exec to step down)
  • FLNC -1.3% (luence and Nine Additional Energy Market Organisations Issue Open Letter to European Policy Makers and the Media regarding the REPowerEU Plan)

Analyst comments:

  • AOS -3.4% (downgraded to Neutral from Outperform at Robert Baird)
  • CDLX -3.4% (downgraded to Equal Weight from Overweight at Wells Fargo)
  • HAYW -3.1% (downgraded to Neutral from Outperform at Robert Baird)
  • JELD -2.5% (downgraded to Equal Weight from Overweight at Barclays)
  • DG -2.1% (downgraded to Neutral from Buy at Citigroup)
  • FISV -2% (downgraded to Equal Weight from Overweight at Wells Fargo)
  • AAT -1.7% (downgraded to Sector Weight from Overweight at KeyBanc Capital Markets)
  • FAST -1.7% (downgraded to Neutral from Outperform at Robert Baird)
  • FIS -1.6% (downgraded to Equal Weight from Overweight at Wells Fargo)
  • GGG -1.6% (downgraded to Neutral from Outperform at Robert Baird)
  • FELE -1.5% (downgraded to Neutral from Outperform at Robert Baird)
  • CI -1.4% (downgraded to Hold from Buy at Jefferies)
  • EIX -1.1% (downgraded to Underperform from Neutral at BofA Securities)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:

  • FRC +5.2%, TSM +1.7%

Other news:

  • TBPH +15.9% (TBPH to sell all of its units in Theravance Respiratory to RPRX for over $1.5 bln)
  • AMYT +11.9% (FDA grants Orphan Drug Designation to Mycapssa for the treatment of Carcinoid Syndrome)
  • GRBK +7.3% (to join S&P SmallCap 600)
  • TGA +6.9% (Transglobe Energy to be acquired by VALLCO Energy (EGY) in stock-for-stock strategic business combination)
  • CLNN +5.9% (report significantly improved survival in ALS patients initially treated with CNM-Au8 compared to initially randomized placebo treated participants during the long-term open-label extension of its RESCUE-ALS trial)
  • ANGI +5.6% (report June performance metrics)
  • MRNS +5.4% (entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $110 mln)
  • VCYT +4.2% (new data show that its GSC is highly accurate in re-classifying lung cancer risk)
  • VCTR +2.6% (reports June AUM)
  • DBRG +1.8% (acquires majority stake in GD Towers in partnership with Brookfield (BIP))

Analyst comments:

  • FLYW +2.1% (upgraded to Buy from Neutral at Goldman)
  • COST +0.8% (upgraded to Buy from Hold at Deutsche Bank)

>>> US Early premarket gappers

Early premarket gappers

  • Gapping up:
    • TBPH +18.1%, GRBK +8.2%, TGA +6.3%, INVA +6%, ANGI +5.6%, VCYT +4.2%, WAFD +2.9%, VCTR +2.8%, DBRG +1.8%, HASI +1.6%, TSM +1.5%, RC +1.1%, FLNC +1.1%
  • Gapping down:
    • CFRX -75.7%, EGY -14.6%, ERIC -8.3%, AZTA -6.2%, BLU -6.1%, GFI -3.4%, AU -3.4%, COKE -3.3%, TTE -3.1%, GOL -3%, SHEL -2.7%, HTA -2.3%, OIH -2.1%, BP -2.1%, GDX -2.1%, IAG -2.1%, HAL -1.9%, PSX -1.9%, FLYW -1.8%, USO -1.8%, RTX -1.7%, XLE -1.7%, NVAX -1.5%, SLV -1.5%, SLB -1.3%, COP -1.3%, GOLD -1.3%, TSLA -1.2%, BTG -1.2%, GLD -1.1%, MOH -0.8%, ESTC -0.8%, CMTL -0.7%

>>> Europe : Brokers Upgrades & Downgrades - 14th of July 2022 V2(+)

>>> Up
* DNB Bank Raised to Overweight at JPMorgan; PT 235 kroner
* Nel Raised to Buy at HSBC; PT 17 kroner

>>> Down
* Adidas Cut to Hold at M.M. Warburg; PT 195 euros V2(+)
* Arkema Cut to Sell at UBS
* BASF Cut to Sell at UBS; PT 37 euros
* Clariant Cut to Sell at UBS
* De' Longhi Cut to Hold at Intesa Sanpaolo; PT 19.80 euros (+)
* Evonik Cut to Neutral at UBS
* Givaudan Cut to Sell at UBS
* Mediclinic Cut to Hold at HSBC; PT 497 pence
* Sabre Insurance Cut to Add at Peel Hunt; PT 210 pence (+)
* Software AG Cut to Underweight at Morgan Stanley; PT 30 euros
* UCB Cut to Neutral at JPMorgan; PT 120 euros
* Wacker Chemie Cut to Neutral at UBS

>>> Initiation
* Accsys Tech Rated New Buy at Canaccord; PT 190 pence
* Oxford Biomedica Rated New Hold at Stifel; PT 525 pence
* Tonies Rated New Hold at Hauck & Aufhaeuser; PT 4 euros

>>> Call
* Galliford Try Outlook Positive, With Strong Pipeline: Peel Hunt
* Hunting Weakness a Buying Opportunity, Berenberg Upgrades to Buy
* Kone Update Shows Bigger China Impact Than Expected, Citi Says (+)
* Morgan Stanley Strategists See European Profit Cuts Accelerating
* UK Defense Firms to Benefit From Tory Leadership Contest: Citi (+)